Table 1.
Demographic and clinical background
| Variables | All patients (n = 36) | Warfarin (n = 13) | Rivaroxaban (n = 23) | P value |
|---|---|---|---|---|
| Age | 36 | 34 ± 11.22 | 36 ± 11.15 | 0.510 |
| Sex | 36 |
Male: 1 (7.69%) Female: 12 (92.31%) |
Male: 6 (26.9%) Female: 17 (73.1%) |
0.382 |
| Predisposing factors | ||||
| OCP or hormone therapy | 7 (19.44%) | 3 (23.1%) | 4 (17.4%) | 0.050 |
| Predisposing genetic hyper coagulopathy | 12 (33.33%) | 7 (53.8%) | 5 (21.7%) | |
| Malignancy | 4 (11.11%) | 0 | 4 (17.39%) | |
| Cerebral lesion | 0.708 | |||
| Ischemic | 25 (69.4%) | 10 (76.9%) | 15 (65.2%) | |
| Hemorrhagic | 11 (36.6%) | 3 (23.1%) | 8 (34.8%) | |
| PHI | 8 (81.82%) | 3 (100%) | 6 (75%) | |
| PHII | 2 (18.18%) | 0 (0%) | 2 (25%) | |
OCP Oral Contraceptive Pill, PH Parenchymal Hemorrhage (European Cooperative Acute Stroke Study classification) Quantitative statistics were shown using Mean and Standard Deviations, Mean ± (SD)